Compare Neurocrine Biosciences Inc (NBIX) vs Noble Corporation plc (NE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Noble Corporation plc — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while Noble Corporation plc trades at $45.83 (market cap $7.33B). The key difference: Neurocrine Biosciences Inc is far larger — about 2.2× Noble Corporation plc's market cap, and Noble Corporation plc pays a 4.36% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | NE | |
|---|---|---|
Market Cap | $15.77B | $7.33B |
Sector | Health | Technology |
52-Week High | $185.50 | $54.37 |
52-Week Low | $123.10 | $26.70 |
Enterprise Value | $15.78B | $8.76B |
Dividend Yield | — | 4.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
Noble Corporation (NE) trades at $45.89, up 0.61% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $46.00. Recent earnings show mixed quarterly results, with a Q1 2026 beat but Q2 and Q4 2025 misses, while annual revenue declined to $3.1 billion in 2026 from $3.3 billion in 2025, and net income fell to $150 million. The company maintains positive cash flow from operations and announced a $0.50 dividend payable in September 2026.
Outlook is cautious due to earnings volatility and revenue contraction, offset by strong cash generation and analyst support. Key risks include ongoing legal investigations and competitive pressures in the offshore drilling sector. The stock presents a balanced opportunity with moderate upside to the price target, but investors should monitor earnings consistency and legal developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →
